CN115698011A - Pb2抑制剂及其制备方法和用途 - Google Patents

Pb2抑制剂及其制备方法和用途 Download PDF

Info

Publication number
CN115698011A
CN115698011A CN202180041967.2A CN202180041967A CN115698011A CN 115698011 A CN115698011 A CN 115698011A CN 202180041967 A CN202180041967 A CN 202180041967A CN 115698011 A CN115698011 A CN 115698011A
Authority
CN
China
Prior art keywords
alkyl
substituted
compound
group
pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180041967.2A
Other languages
English (en)
Other versions
CN115698011B (zh
Inventor
李瑶
陈雷
石宗军
张国彪
王文晶
叶飞
胡刚
贺天成
王浩东
倪佳
张晨
严庞科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tibet Haisike Pharmaceutical Co ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Priority to CN202311238123.4A priority Critical patent/CN117362318A/zh
Publication of CN115698011A publication Critical patent/CN115698011A/zh
Application granted granted Critical
Publication of CN115698011B publication Critical patent/CN115698011B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开一种式(I)的化合物，其立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐、共晶或前药，或含它们的药物组合物，及其作为PB2抑制剂在制备治疗相关疾病的药物中的用途，式(I)中各基团如说明书之定义。Cy1‑L1‑Cy2‑L2‑Cy3 (I)。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN202180041967.2A 2020-07-10 2021-07-09 Pb2抑制剂及其制备方法和用途 Active CN115698011B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311238123.4A CN117362318A (zh) 2020-07-10 2021-07-09 Pb2抑制剂及其制备方法和用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010658037 2020-07-10
CN2020106580379 2020-07-10
CN2020111218392 2020-10-20
CN202011121839 2020-10-20
PCT/CN2021/105622 WO2022007966A1 (zh) 2020-07-10 2021-07-09 Pb2抑制剂及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311238123.4A Division CN117362318A (zh) 2020-07-10 2021-07-09 Pb2抑制剂及其制备方法和用途

Publications (2)

Publication Number Publication Date
CN115698011A true CN115698011A (zh) 2023-02-03
CN115698011B CN115698011B (zh) 2023-10-20

Family

ID=79552271

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311238123.4A Pending CN117362318A (zh) 2020-07-10 2021-07-09 Pb2抑制剂及其制备方法和用途
CN202180041967.2A Active CN115698011B (zh) 2020-07-10 2021-07-09 Pb2抑制剂及其制备方法和用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202311238123.4A Pending CN117362318A (zh) 2020-07-10 2021-07-09 Pb2抑制剂及其制备方法和用途

Country Status (5)

Country Link
US (1) US20230265107A1 (zh)
EP (1) EP4180434A1 (zh)
CN (2) CN117362318A (zh)
TW (1) TW202202500A (zh)
WO (1) WO2022007966A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023196975A1 (en) * 2022-04-08 2023-10-12 Shy Therapeutics, Llc Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854205A (zh) * 2015-12-09 2017-06-16 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
CN108727369A (zh) * 2017-04-25 2018-11-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN109641868A (zh) * 2016-08-30 2019-04-16 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN110637022A (zh) * 2017-04-24 2019-12-31 共晶制药公司 可作为流感病毒复制抑制剂的吡咯并嘧啶衍生物
WO2020125673A1 (zh) * 2018-12-19 2020-06-25 南京药石科技股份有限公司 流感病毒复制抑制剂及其中间体和用途
CN111518094A (zh) * 2019-02-01 2020-08-11 四川大学华西医院 一种抗流感小分子化合物及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ619259A (en) 2009-06-17 2015-07-31 Vertex Pharma Inhibitors of influenza viruses replication
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2018033082A1 (en) * 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106854205A (zh) * 2015-12-09 2017-06-16 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
WO2017133664A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
CN109641868A (zh) * 2016-08-30 2019-04-16 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
CN110637022A (zh) * 2017-04-24 2019-12-31 共晶制药公司 可作为流感病毒复制抑制剂的吡咯并嘧啶衍生物
CN108727369A (zh) * 2017-04-25 2018-11-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2020125673A1 (zh) * 2018-12-19 2020-06-25 南京药石科技股份有限公司 流感病毒复制抑制剂及其中间体和用途
CN111518094A (zh) * 2019-02-01 2020-08-11 四川大学华西医院 一种抗流感小分子化合物及其制备方法和用途

Also Published As

Publication number Publication date
CN117362318A (zh) 2024-01-09
TW202202500A (zh) 2022-01-16
WO2022007966A1 (zh) 2022-01-13
CN115698011B (zh) 2023-10-20
US20230265107A1 (en) 2023-08-24
EP4180434A1 (en) 2023-05-17

Similar Documents

Publication Publication Date Title
CN104837829B (zh) 抑制剂化合物
ES2708211T3 (es) 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
CN105814054B (zh) 作为tnf活性调节剂的稠合咪唑和吡唑衍生物
CN114615981A (zh) Kras g12d抑制剂
KR102376354B1 (ko) 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도
TW202214605A (zh) 免疫調節劑、組合物及其方法
WO2021087018A1 (en) Pyridazinones as parp7 inhibitors
CN112135824A (zh) 作为免疫调节剂的杂环化合物
CN101636388B (zh) 化合物637：作为pde4抑制剂的吡啶并嘧啶二酮
EP4304720A1 (en) Mta-cooperative prmt5 inhibitors
TW201014855A (en) Compounds for the treatment of hepatitis C
WO2021249057A1 (zh) 杂环化合物及其用途
WO2008016131A1 (fr) Composé hétérocyclique à cycles fusionnés
CN105073736B (zh) 作为呼吸道合胞病毒抗病毒剂的喹喔啉酮和二氢喹喔啉酮
CN114423753A (zh) 作为cd38抑制剂的杂双环酰胺
TW201734021A (zh) 布魯頓氏（ｂｒｕｔｏｎ）酪胺酸激酶抑制劑及其使用方法
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
CN113166110B (zh) 2-氨基嘧啶类化合物及其应用
KR20170075756A (ko) 카르바졸 유도체
US20230035184A1 (en) Diarylthiohydantoin compound as androgen receptor antagonist
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
KR20190091339A (ko) Pi3k델타 억제제로서의 이미다조[1,5-a]피라진 유도체
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
TWI705965B (zh) 新穎三環化合物
CN115698011A (zh) Pb2抑制剂及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20231219

Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region

Patentee after: Tibet Haisike Pharmaceutical Co.,Ltd.

Address before: 611130 No.136 Baili Road, Chengdu cross strait science and Technology Industrial Development Park, Wenjiang District, Chengdu City, Sichuan Province

Patentee before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right